Evidence map›Paper›PMID 33280425›Full record

Trial reportDiabetes & vascular disease research

Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12).

Aslam Amod, John B Buse, Darren K McGuire, Thomas R Pieber, Rodica Pop-Busui, Richard E Pratley, Bernard Zinman, Marco Bo Hansen, Ting Jia, Thomas Mark and 2 more

Registry-linked trialOpen access · diamondAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01959529 (A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01959529 phase3completednot on this map

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

TypeinterventionalSponsorNovo Nordisk A/SRan2013 to 2016Enrolled7,637ConditionsDiabetes, Diabetes Mellitus, Type 2Armsinsulin degludec, insulin glargine
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 6 countries.

Aslam AmodDepartment of Diabetes and Endocrinology, Life Chatsmed Garden Hospital and Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.ORCID 0000-0002-9172-1019
John B BuseSchool of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Darren K McGuireDepartment of Internal Medicine, University of Texas Southwestern Medical Center and Parkland Health and Hospital System, Dallas, TX, USA.
Thomas R PieberDepartment of Internal Medicine, Medical University of Graz, Graz, Austria.
Rodica Pop-BusuiDepartment of Internal Medicine, Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA.
Richard E PratleyAdventHealth Translational Research Institute, Orlando, FL, USA.
Bernard ZinmanDepartment of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Marco Bo HansenNovo Nordisk A/S, Søborg, Hovedstaden, Denmark.
Ting JiaNovo Nordisk A/S, Søborg, Hovedstaden, Denmark.
Thomas MarkNovo Nordisk A/S, Søborg, Hovedstaden, Denmark.
Neil R PoulterSchool of Public Health, Faculty of Medicine, Imperial College London, London, UK.
DEVOTE Study Group
Novo Nordisk (Denmark) · DKImperial College London · GBMedical University of Graz · ATMount Sinai Hospital · CAParkland Health & Hospital System · USTranslational Research Institute for Metabolism and Diabetes · USUniversity of KwaZulu-Natal · ZAUniversity of Michigan · USUniversity of North Carolina at Chapel Hill · US

Funding

Glycemia Reduction Approaches in Diabetes: A comparative effectiveness studyU01DK098246 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI KRAUSE-STEINRAUF, HEIDI, LACHIN, JOHN M · 2012 to 2022
$238.9M
Re-Entry Supplement: Investigation of Oral Microbial Enzymes for the Detection and Treatment of Periodontal DiseaseUL1TR002489 · NCATS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, SHAHEEN, NICHOLAS J · 2018 to 2022
$48.6M
PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1DUC4DK101108 · NIDDK · JOSLIN DIABETES CENTER · PI DORIA, ALESSANDRO, MAUER, S. MICHAEL · 2013 to 2018
$31.6M
RADIANT Clinic and Data Coordinating CenterU54DK118612 · NIDDK · UNIVERSITY OF CHICAGO · PI Louis H. Philipson, Miriam Sargon Udler · 2018 to 2026
$21.9M
Final clinical studies for submission of a pre-market approval application to the FDA for a Bionic Pancreas that automates type 1 diabetes managementUC4DK108612 · NIDDK · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI BECK, ROY W., DAMIANO, EDWARD · 2015 to 2016
$13.5M
Pilot & Feasibility ProgramP30DK124723 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI P Darrell Neufer · 2020 to 2026
$11.0M
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver DiseaseR01DK119913 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI MCCLAIN, DONALD A. · 2019 to 2024
$3.3M
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic NeuropathyR01DK107956 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BUSUI (POP-BUSUI), RODICA, FELDMAN, EVA LUCILLE · 2016 to 2020
$3.0M
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD TrialR01HL110380 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BUSE, JOHN BERNARD, WAGNER, MICHAEL JAY · 2012 to 2015
$2.4M
Towards Glucose Transporter-Mediated Glucose-Responsive Insulin Delivery with Fast ResponseR01DK112939 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, SONG · 2018 to 2022
$2.2M
Randomized Explanatory Trial of a Mediterranean Dietary Pattern Weight Loss Intervention for Primary Care PracticesR61HL142680 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KEYSERLING, THOMAS C, SAMUEL-HODGE, CARMEN D · 2019 to 2019
$759k
NCATS NIH HHS UL1 TR002489NHLBI NIH HHS R01 HL110380NHLBI NIH HHS R61 HL142680NIDDK NIH HHS P30 DK124723NIDDK NIH HHS R01 DK107956NIDDK NIH HHS R01 DK112939NIDDK NIH HHS R01 DK119913NIDDK NIH HHS U01 DK098246NIDDK NIH HHS U54 DK118612NIDDK NIH HHS UC4 DK101108NIDDK NIH HHS UC4 DK108612
6 · The paper itself

Abstract

aimTo investigate risk factors associated with kidney disorders in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk.

methodsIn DEVOTE, a cardiovascular outcomes trial, 7637 patients were randomised to insulin degludec (degludec) or insulin glargine 100 units/mL (glargine U100), with standard of care. In these exploratory post hoc analyses, serious adverse event reports were searched using Standardised MedDRA

resultsOver 2 years, eGFR (mL/min/1.73 m

conclusionOur findings indicate that traditional, non-modifiable risk factors for kidney disorders apply to insulin-treated patients with T2D at high CV risk.

trial registrationNCT01959529 (ClinicalTrials.gov).

Indexed as

Acute Kidney InjuryDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlomerular Filtration RateHeart Disease Risk FactorsHumansHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingKidneyMaleMiddle AgedRenal Insufficiency, ChronicRisk AssessmentTime FactorsHypoglycemic Agentsinsulin degludecInsulin GlargineInsulin, Long-ActingCardiovascularchronic renal failureCVOTdiabetic kidney diseaseinsulin analoguestype 2 diabetes mellitus

Identifiers

PMID33280425
PMCPMC7919227
OpenAlexW3113106114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.